Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2005

View Archived Issues

New data on the efficacy of diindolemethane in cervical neoplasia

CaMKII inhibition: potential cardioprotective strategy against structural heart disease

Favorable results for GW-6604 from preclinical models of liver fibrosis

Clinical evidence for the benefits of sildenafil citrate in PAH

MEDI-524 reported safe in children at high risk of RSV infection

IMT-504 stimulates immune response to vaccines in preclinical models

MHLW recommends approval of Mylotarg and Salagen

Tentative approval for Biovail's Zolpidem ODT

Rectogesic launched in U.K.

Enrollment begins in NOBORI 1 study of drug-eluting coronary stent

Avantogen, new name for Australian Cancer Technology

Organon obtains license for Merck's novel oral contraceptive

Vicuron files amendment to anidulafungin NDA

Serono profiles latest events

In vivo efficacy of atiprimod in SCID models of MM

Treatments for erectile dysfunction investigated for asthma

In vivo data demonstrates that CVT-6883 may be useful for chronic lung diseases

New therapeutics for cancer disclosed in recent patents

Ranbaxy receives tentative approval for lamivudine tablets

New agents claimed for the treatment of diabetes

Priority review for Remicade for ulcerative colitis

Preclinical data for BXL-6285 in interstitial cystitis models

Neumune IND filed in U.S.

Pfizer responds to claims linking Viagra to NAION

(-)-BPAP HCL protects cells from hypoxia-induced injury

Titrated pramlintide benefits patients with type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...